new_0222_0301|OLMA|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0301|OLMA|1|Olema Pharmaceuticals inc Total Current Assets (Quarterly) (USD)|Olema Pharmaceuticals inc Cash and Short Term Investments (Quarterly) (USD)|Olema Pharmaceuticals inc Inventories (Quarterly) (USD)|Olema Pharmaceuticals inc Net PP&E (Quarterly) (USD)|Olema Pharmaceuticals inc Goodwill and Intangibles (Quarterly) (USD)|Olema Pharmaceuticals inc Total Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Current Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Long Term Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Deposits (Quarterly) (USD)|Olema Pharmaceuticals inc Book Value (Quarterly) (USD)|Olema Pharmaceuticals inc Retained Earnings (Quarterly) (USD)|Olema Pharmaceuticals inc Treasury Stock (Quarterly) (USD)|Olema Pharmaceuticals inc EV to Revenues|Olema Pharmaceuticals inc EV to Earnings|Olema Pharmaceuticals inc EV to Free Cash Flow|Olema Pharmaceuticals inc EV to Assets (Quarterly)|Olema Pharmaceuticals inc PS Ratio|Olema Pharmaceuticals inc PE Ratio|Olema Pharmaceuticals inc Price to Book Value|Olema Pharmaceuticals inc PEG Ratio|Olema Pharmaceuticals inc Debt to Equity Ratio|Olema Pharmaceuticals inc Dividend Yield|Olema Pharmaceuticals inc Shareholder Yield (TTM)|Olema Pharmaceuticals inc Percent of Shares Outstanding Short|Olema Pharmaceuticals inc Total Receivables (Quarterly) (USD)|Olema Pharmaceuticals inc Total Payables (Quarterly) (USD)|Olema Pharmaceuticals inc Total Capital Stock (Quarterly) (USD)|Olema Pharmaceuticals inc Return on Invested Capital|Olema Pharmaceuticals inc Quality Ratio Score|Olema Pharmaceuticals inc Momentum Score|Olema Pharmaceuticals inc Beta (1Y)|Olema Pharmaceuticals inc Sustainable Growth Rate (TTM)|Olema Pharmaceuticals inc Institutional Investor Ownership Percentage|Olema Pharmaceuticals inc Average Diluted Shares Outstanding (Quarterly)|Olema Pharmaceuticals inc Total Employees (Annual)|Olema Pharmaceuticals inc EPS Diluted (Quarterly) (USD)|Olema Pharmaceuticals inc Shares Outstanding|Olema Pharmaceuticals inc Repurchase of Capital Stock (Quarterly) (USD)|Olema Pharmaceuticals inc Ordinary Shares Number (Quarterly)|Olema Pharmaceuticals inc Payout Ratio|Olema Pharmaceuticals inc Quick Ratio (Quarterly)|Olema Pharmaceuticals inc Normalized Diluted EPS (Quarterly) (USD)|Olema Pharmaceuticals inc Stock Buybacks (Quarterly) (USD)|Olema Pharmaceuticals inc Effective Tax Rate (TTM)|Olema Pharmaceuticals inc Return on Equity|Olema Pharmaceuticals inc Net Income (TTM) (USD)|Olema Pharmaceuticals inc Revenue (TTM) (USD)|Olema Pharmaceuticals inc Dividend Per Share (Quarterly) (USD)|Olema Pharmaceuticals inc Revenue (Quarterly) (USD)|Olema Pharmaceuticals inc Gross Profit (Quarterly) (USD)|Olema Pharmaceuticals inc SG&A Expense (Quarterly) (USD)|Olema Pharmaceuticals inc Pre-Tax Income (Quarterly) (USD)|Olema Pharmaceuticals inc Net Income (Quarterly) (USD)|Olema Pharmaceuticals inc Net Interest Income (Quarterly) (USD)|Olema Pharmaceuticals inc Price (USD)|Olema Pharmaceuticals inc Total Return Price (USD)|Olema Pharmaceuticals inc Enterprise Value (USD)|Olema Pharmaceuticals inc 30-Day Average Daily Volume|Olema Pharmaceuticals inc 1 Year Price Returns (Daily)||
new_0222_0301|OLMA|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0301|OLMA|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_0222_0301|OLMA|5|121.833333333|121.833333333||121.833333333||121.833333333|121.833333333|121.833333333||121.833333333|121.833333333||||1.44918032787||||1.45345345345|||1.45345345345||15.1666666667||121.833333333|121.833333333|||29.5|30|||91.375|205|91.375|35.6923076923|91.4|121.833333333|||91.375||||91.4|||||91.375|91.375|91.375|91.375|1.45345345345|1.45345345345|1.45345345345|1.44078947368|1.46913580247||
new_0222_0301|OLMA|6|6|6||6||6|6|6||6|6||||305||||333|||333||30||6|6|||2|3|||8|2|8|13|5|6|||8||||5|||||8|8|8|8|333|333|333|304|81||
new_0222_0301|OLMA|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0301|OLMA|201912|0.103|0.068||0.026||10.726|1.378|9.348||-10.594|-10.762|||||||||||||||0.935||||||||14.0986||-0.0721|||37.5197|||-0.0721|||||||||0.107|-1.017|-1.017||||||||
new_0222_0301|OLMA|202003||||||||||||||||||||||||||||||||||14.0986||-0.1201||||||-0.1201|||||||||0.248|-1.693|-1.693|-0.65|||||||
new_0222_0301|OLMA|202006||||||||||||||||||||||||||||||||||14.0986||-0.174||||||-0.174|||||||||0.539|-2.453|-2.453|0.033|||||||
new_0222_0301|OLMA|202009|129.087|127.824||0.024||5.273|5.273|||125.41|-22.963||||||||16.3357|||||1.0918||0.097|0.003|||||||37.5197|22|-0.2589|40.1697|-2.289|39.3082|||-0.2091||||-13.007|||||3.195|-7.844|-7.844|0.023|51|51|1920.8307||||
new_0222_0301|OLMA|202012|342.137|338.549||0.075||4.585|4.585|||338.137|-33.094||||-77.8732||||5.5893|||||1.8086||0.917|0.003|||||||39.3082|37|-0.5|39.3082||39.3082|||-0.5||||-22.121|||||3.842|-10.131|-10.131|0.001|48.08|48.08|1551.3893|87569.1333||42.45|39.92
new_0222_0301|OLMA|202103|330.265|326.968||0.526||5.277|5.277|||326.024|-48.433||||-34.3521||||4.0881|||||2.1434||0.49|0.003|||||||39.3258||-0.39|40.1697||40.1697|||-0.39||||-35.767|||||4.758|-15.339|-15.339|0.111|33.18|33.18|1005.8626|226091.9||28.05|27.96
new_0222_0301|OLMA|202106|320.854|318.144||0.866||8.146|8.146|||314.084|-64.839||||-21.107||||3.5235|||||5.7068||0.452|0.003|||||||39.4153||-0.42|39.5526||39.5526|||-0.42||||-49.72|||||4.612|-16.406|-16.406|0.117|27.98|27.98|788.5377|280866.2667||23.48|29.92
new_0222_0301|OLMA|202109|308.28|305.954||0.975||8.901|8.901|||300.894|-82.552||||-18.7418||||3.6346|||||6.0811||0.373|0.003||||1.7402|||39.6077||-0.45|39.6813||39.6813|||-0.45||||-59.589|||||5.239|-17.713|-17.713|0.105|27.56|27.56|787.6626|364130.2667|-82.8431|27|8.75
new_0222_0301|OLMA|202112|290.685|287.25||4.72||11.377|9.019|2.358||284.568|-104.19||||-1.6312||||1.309|||||9.6377||0.111|0.003|||1|1.9879|||39.7451|74|-0.54|39.7973||39.7973|||-0.54||||-71.096|||||5.782|-21.638|-21.638|0.109|9.36|9.36|85.2527|1317534.5667|-80.5324|6.43|4.68
new_0222_0301|OLMA|202203|||||||||||||||1.6593||||0.7047||||||||||||||||||||||||||||||||||||4.97|4.97|-86.7229|445463.9667|-88.854||